MAb therapy for advanced CTCL has been proposed [3] and numerous trials with alemtuzumab (anti-CD52) have shown modest to moderate clinical effects [35], [36], [37]. This evidence concerns the gene CD52 and primary cutaneous T-cell non-Hodgkin lymphoma.